Clinical Trial

Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
In a real-world setting, this study systematically evaluates the clinical efficacy and safety of guselkumab (GUS) in the treatment of ulcerative colitis (UC), encompassing multi-dimensional outcomes including clinical remission, biochemical remission, endoscopic remission, histologic healing, and intestinal ultrasound changes.
Trial Details
NCT Number NCT07726888
Lead Sponsor Second Affiliated Hospital of Wenzhou Medical University
Collaborators: Xian-Janssen Pharmaceutical Ltd.
Conditions Ulcerative Colitis (Disorder), Guselkumab
Enrollment 97 participants
Start Date 2026-08-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-07